CML is an ideal model to test this hypothesis as the disease is initiated and initially maintained solely by BCR::ABL, which is targeted in the clinic by TKIs, a treatment effective in inducing disease remission, but often not curative. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.